Publicado el

CareDx to Host Symposium Covering Innovation in Multimodal Surveillance Including AiCAV for Post-Cardiac Transplant Care

Loading

CareDx to Host Symposium Covering Innovation in Multimodal Surveillance Including AiCAV for Post-Cardiac Transplant Care

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will host a symposium to describe the latest innovations in post-cardiac transplant care at the HFSA (Heart Failure Society of America) Annual Scientific Meeting 2022 taking place in Washington, D.C., September 30 – October 3.

“We look forward to HFSA where we will share more on our AI Heart Platform with AiCAV™, a new offering in development that will help to inform clinicians in their assessment of cardiac allograft vasculopathy risk,” said Reg Seeto, CEO and President of CareDx. “For over two decades, CareDx has been leading innovation to improve outcomes for transplant patients and we are extremely proud to extend this leadership with AiKidney™ and AiCAV.” Read the full press release on CareDx.com.

Loading
Publicado el

Medical Debt Makes the Sick Sicker

Loading

— Better and broader insurance coverage is essential

Most physicians have sworn an oath to “abstain from whatever is deleterious” to our patients. Yet our medical institutions harm patients daily. They dun them for medical bills they can’t afford, often leaving them unable to pay their rent or mortgage, or buy enough to eat.

That accusation isn’t hyperbole, it’s a finding from our analysis — published this month in JAMA Network Open — of Census Bureau surveys on medical indebtedness. 
Read more in MedPage Today.

Loading
Publicado el

Remdesivir-Resistant Version of COVID-19 Detected in Organ Transplant Recipients

Loading

Recent studies have shown that patients with weakened immune systems—which enables the virus that causes COVID-19 to remain longer in the body, copy itself, and continually change—may enable the development of new, slightly different versions of the virus (variants). These people include those treated with drugs that suppress the immune system to keep it from rejecting a newly transplanted organ.

A new study led by researchers at NYU Grossman School of Medicine and NYU Long Island School of Medicine shows that two people with kidney transplants who were treated with immunosuppressive drugs, and who later had a lengthy COVID-19 infection, developed a version of the virus with a genetic change (mutation) that made it resistant to the antiviral therapy remdesivir. Read more from NYU Langone Health News Hub.

Loading
Publicado el

Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions

Loading

Study Reaffirms Benefits of AlloMap, the Industry’s Only Gene-Expression Profiling Blood Test, for Heart Transplant Rejection Surveillance

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a new peer-reviewed publication showing that AlloMap®, the industry’s only gene-expression profiling (GEP) blood test to non-invasively assess graft rejection by monitoring immune quiescence in heart transplant patients,1 resulted in less pain and fewer adverse events compared to heart biopsy.2 The study also highlights that the associated AlloMap blood test draw can be performed in the patient’s home to help reduce the risk of exposure to infection. Read the complete press release on CareDx.com.

Loading
Publicado el

CareDx Congratulates Board Member Dr. Grace Colón for Being Named Healthcare Innovator on Top 50 Most Powerful Latinas List

Loading

The Association of Latino Professionals For America Recognizes the Most Powerful Latinas in Business, Technology, Healthcare, and Non-Profit Sectors

BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Dr. Grace Colón, a member of its Board of Directors, has been named on the 2022 Most Powerful Latinas list by The Association of Latino Professionals For America (ALPFA).

“We congratulate Dr. Colón for being named a healthcare innovator by ALPFA and for her significant contribution in driving innovation to improve patient care,” said Michael D. Goldberg, Chairman of the Board, CareDx. “As Chair of CareDx’s Science and Technology Committee she has played an invaluable role in helping shape the company’s innovation agenda focused on improving the transplant patient journey.”
Read the complete press release on CareDx.com.

Loading
Publicado el

Patient receives Pacific Northwest’s first donation-after-circulatory-death heart transplant

Loading

On Aug. 11, LifeCenter Northwest, the Organ Procurement Organization for Washington, and UW Medicine’s heart transplant team together facilitated the Pacific Northwest’s first donation-after-circulatory-death (DCD) heart transplant.

The patient, Ryan Stovall, 48, a resident of Beaver Creek, Oregon, is recovering well in Seattle. Read more from News Medical Life Sciences.

Loading
Publicado el

Everything You Need to Know About Being a Living Liver Donor

Loading

With over 105,000 people on the national transplant waiting list, it should be no surprise that organ donation is one of the most important medical procedures of our time. In 2021 alone, more than 11,800 people on the national transplant list were waiting specifically for a liver transplant.

But what does the journey of a liver transplant involve, exactly? And what does this process look like for living liver donors who make the choice to donate a part of their liver?
Read more from Healthline.

Loading
Publicado el

What you need to know about COVID-19 in 2022

Loading

As has been previously reported and most already know, the virus that causes COVID-19 changes over time. The updated COVID-19 vaccine bivalent boosters include components of the original virus strain and the Omicron variant. This updated booster is called a bivalent COVID-19 vaccine booster because it is effective against two different strains of the virus

The updated COVID-19 vaccine boosters are designed to give you broad protection against COVID-19, including better protection against the Omicron variant. Read more from the National Kidney Foundation.

Loading
Publicado el

Eye Damage Can Start in Prediabetes

Loading

— Study found significant corneal nerve damage even before full-blown type 2 diabetes

Elevated blood glucose poses a threat to the eyes even prior to a diabetes diagnosis, according to a Dutch population study.

In cross-sectional data of Maastricht Study participants, a more adverse glucose metabolism status was linked with a lower z score of corneal nerve fiber measures compared with a normal status (-0.14, 95% CI -0.25 to -0.04, P for trend=0.001), reported Sara Mokhtar, a PhD student at Maastricht University Medical Center in the Netherlands, and colleagues. Read more in MedPage Today.

Loading